MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
about
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standardsCirculating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlookMyeloid suppressor cells and immune modulation in lung cancerMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesHampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancerMyeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implicationsRegulation of tumor metastasis by myeloid-derived suppressor cellsCirculating biomarkers in advanced renal cell carcinoma: clinical applicationsImproving cancer immunotherapy by targeting the STATe of MDSCsMyeloid-derived suppressor cells in the tumor microenvironment: expect the unexpectedReduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput dataMyeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomicsPatient-tailored modulation of the immune system may revolutionize future lung cancer treatment.Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease.A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patientsSunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.Complexity and challenges in defining myeloid-derived suppressor cellsTyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.Intravascular staining for discrimination of vascular and tissue leukocytes.Myeloid derived suppressor cells in chronic myeloid leukemia.Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell CarcinomaExploiting natural anti-tumor immunity for metastatic renal cell carcinoma.Macrophage Migration Inhibitory Factor Secretion Is Induced by Ionizing Radiation and Oxidative Stress in Cancer Cells.A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development.TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesisCD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment.Transcriptional regulation of myeloid-derived suppressor cells.Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.Contrasting effects of sunitinib within in vivo models of metastasis.Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body RadiotherapyHuman Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironmentTumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories.The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.
P2860
Q26744395-06538A0D-6C55-4114-B107-74A1D3CEC15AQ26823035-DF805C02-7D94-46AF-B9EC-18ADC81547E2Q26823251-D0A57C7D-0920-4F4E-899C-519EA111080BQ26852437-F3B0470A-872E-432A-83E7-5161A13AF516Q26863418-D5C4293D-3F6E-4A9A-9532-DE60D827701AQ27014189-4BE051E0-12FB-4853-9871-344DB00A7A3FQ27022125-D86FD6B7-BB28-44E4-AC18-5D6703632EDFQ27023770-964844BF-08DE-48F9-9A27-98F0F78CAF54Q28066797-7BD432E8-5273-4287-9912-02AAFC54A416Q28084627-EA02036E-5250-4236-919B-05EDEF31B137Q30317831-EE9AE241-0EBB-48F4-B99E-C17AFBC2B833Q33564156-E0171A51-AC18-45C9-92C1-4C3CC4FAB561Q33592056-2A5E550C-FB3E-440F-A084-13DD1D4DA5AFQ33889439-494A2434-6C9F-4A1A-9ACC-226688728E19Q33996767-6AA89F82-7B81-4A4F-8273-70BD604B77FCQ34502899-72F0D51C-82B3-4B76-B88E-D9B163DF1D22Q34517267-0F195402-7FFF-4B89-BECA-DC43A9263179Q34570094-CCA87F49-F10B-4EF3-8638-028D3A15C050Q35506659-C17E9C37-29A1-4B42-908E-5CC8B7559869Q35509317-C4B46DEA-511D-40F3-8890-91B5506CE10EQ35534962-B6B77425-FE16-4F85-903D-F7AFBC2E1884Q35578622-CB26C2DC-82DE-426A-B193-6E97DA5B7A37Q35596407-B718700E-6A79-4BE7-AC79-AEDCDFC57A5FQ35609094-2F4F08BC-6819-473A-8850-1EBFDA1CEBEFQ35675548-2F98AFBD-4672-43F6-A6F0-371FC50BC9EAQ35887319-10E41812-DDB0-4072-99ED-60361C023FBCQ35888073-CF581933-D517-4F25-A4FD-C7990AA469D8Q36107975-F9798DFB-8F83-458E-BB7B-5036D40A1853Q36108579-19994C42-A20E-4EF7-A795-7AD1158DB1D9Q36242193-B1BEE2C9-CAC7-4C05-9170-281811B518B8Q36322351-BF2FF841-C55B-4474-91DB-5C7B0A0988EBQ36335477-08B9F379-A8E5-4D91-AB97-630D0CA1AF6FQ36394262-40F2C283-F651-4A1C-B8F4-712E81B7081BQ36483105-38860204-2851-4D69-98CE-6FF168822B92Q36489379-10D63ACD-20F6-40A1-9F61-847DBD4A3647Q36572163-1B9DC4D2-69CE-491A-A831-C02F381E21EAQ36587186-96C8296C-3382-4C92-AB83-CA735330B80BQ36685551-70226EA7-7D1D-48ED-9FB9-069E222B0FF8Q36918248-178ABDED-CF81-4FD1-A937-A2E0483A9509Q36938866-BD7795D2-F142-4663-B8B4-C7144468B108
P2860
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
@ast
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
@en
type
label
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
@ast
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
@en
prefLabel
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
@ast
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
@en
P2093
P2860
P1476
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
@en
P2093
Brian Rini
James Finke
Jennifer Ko
Joanna Ireland
Pat Rayman
Peter Cohen
P2860
P304
P356
10.1016/J.INTIMP.2011.01.030
P577
2011-02-11T00:00:00Z